Pharm'Up 
Precision medicine is no longer a futuristic concept—it is at the forefront of modern cancer care, with targeted therapies leading to better patient outcomes. With over half of all cancer patients receiving treatment in community settings, ensuring these practices can deliver cutting-edge care is a critical and complex challenge. The provided text, authored by experts including Dr. John Burke, highlights the significant barriers to adopting precision medicine in community oncology and outlines a comprehensive strategy to overcome them.
Persistent Challenges in Community-Based Care
The adoption of precision medicine in community settings faces a number of hurdles:
- Logistical Barriers: Community practices often struggle to keep up with the latest biomarker testing guidelines. This is compounded by slow turnaround times for test results, challenges in obtaining sufficient tissue samples for testing, and limited access to specialized technical assistance for interpreting complex results.
- Knowledge and Educational Gaps: A lack of appropriate biomarker testing can stem from gaps in physician education. Without comprehensive training on the latest genomic technologies and guidelines, physicians may not be aware of all the opportunities for their patients.
- Financial and Social Inequities: The high cost of comprehensive genomic profiling can create significant financial barriers for patients. This issue is particularly acute in rural areas, exacerbating health disparities based on a patient’s geography, socioeconomic status, race, or ethnicity.
A Coordinated Approach to Overcoming Barriers
Organizations like The US Oncology Network, supported by McKesson, are working to address these challenges by providing a robust ecosystem of support to independent community-based providers. This network, which includes approximately 3,300 providers across 29 states, empowers practices to deliver high-quality, advanced care.
Key strategies being employed include:
- Advanced Education and Resources: The network has developed educational programs to help oncologists interpret molecular test results, select appropriate tests for specific cancers, and integrate best practices into tissue biopsy workflows. This aims to close the knowledge gap and ensure tests are utilized effectively.
- Expanding Clinical Trials: Community practices are being empowered to serve as clinical trial sites. This is crucial for matching eligible patients with cutting-edge treatments and helps to address racial and ethnic disparities in clinical research by expanding the patient pool beyond major academic centers. This can also reduce financial and logistical burdens on patients who would otherwise have to travel long distances for trial participation.
- Technology Integration: Technology-driven tools are being integrated directly into the electronic health record (EHR). These tools can support appropriate biomarker test selection, facilitate electronic ordering, and identify patients who are eligible for clinical trials based on their biomarker test results.
A Comprehensive Vision for the Future
The text concludes with a forward-looking vision for community oncology. By combining ongoing education, technology enhancements, clinical trial support, and assistance with interpreting complex test results, community practices can deliver cutting-edge therapies. These advancements are transforming how cancer care is provided, ensuring that all patients, regardless of their location or background, have access to the most advanced and effective treatments available.
About the Author
